BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20001212)

  • 21. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
    Hiscox S; Barnfather P; Hayes E; Bramble P; Christensen J; Nicholson RI; Barrett-Lee P
    Breast Cancer Res Treat; 2011 Feb; 125(3):659-69. PubMed ID: 20354780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
    Poulsen SA
    Expert Opin Ther Pat; 2010 Jun; 20(6):795-806. PubMed ID: 20476848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
    Hao HF; Takaoka M; Bao XH; Wang ZG; Tomono Y; Sakurama K; Ohara T; Fukazawa T; Yamatsuji T; Fujiwara T; Naomoto Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):744-9. PubMed ID: 22705303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Src and focal adhesion kinase as therapeutic targets in cancer.
    Brunton VG; Frame MC
    Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal adhesion kinase and cancer.
    Golubovskaya VM; Kweh FA; Cance WG
    Histol Histopathol; 2009 Apr; 24(4):503-10. PubMed ID: 19224453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting AAC-11 in cancer therapy.
    Faye A; Poyet JL
    Expert Opin Ther Targets; 2010 Jan; 14(1):57-65. PubMed ID: 20001210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focal adhesion kinase as potential target for cancer therapy (Review).
    Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Wang ZG; Takaoka M
    Oncol Rep; 2009 Nov; 22(5):973-9. PubMed ID: 19787209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focal adhesion kinase as a regulator of cell tension in the progression of cancer.
    Tilghman RW; Parsons JT
    Semin Cancer Biol; 2008 Feb; 18(1):45-52. PubMed ID: 17928235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focal adhesion kinase: exploring Fak structure to gain insight into function.
    Hall JE; Fu W; Schaller MD
    Int Rev Cell Mol Biol; 2011; 288():185-225. PubMed ID: 21482413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Pyk2 for therapeutic intervention.
    Lipinski CA; Loftus JC
    Expert Opin Ther Targets; 2010 Jan; 14(1):95-108. PubMed ID: 20001213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of FAK in tumor metabolism and therapy.
    Zhang J; Hochwald SN
    Pharmacol Ther; 2014 May; 142(2):154-63. PubMed ID: 24333503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
    Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
    Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging roles of focal adhesion kinase in cancer.
    Tai YL; Chen LC; Shen TL
    Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.